Chiral Quest receives U.S. patent for DIOP* ligand family
Chiral Quest, Inc. today announced that the U.S. Patent and Trademark Office has issued a patent (No. 6,576,772) covering composition of matter for chiral bisphosphine ligands derived from D-mannitol to The Penn State Research Foundation, a non-profit corporation. Professor Xumu Zhang, Chiral Quest's Chief Technology Officer is the inventor on the patent. Chiral Quest, Inc. is the exclusive licensee of the patent.
DIOP* ligand differs from well-known DIOP ligand in its conformational stability. Methyl groups and other substituents in DIOP* are oriented in equatorial positions. This conformational difference has produced a dramatic increase of enantioselectivity for the hydrogenation of enamides. Rhodium-complexes of DIOP* form efficient catalysts for the asymmetric hydrogenation of enamides.
Chiral bisphosphines are the sixth family of ligands to be added to Chiral Quest's patent portfolio.
"We are the only life sciences chiral chemistry company in the market with proprietary ligands for chiral reactions representing each class of important chiral phosphines," commented Alan Roth, Ph.D., President and Chief Executive Officer of Chiral Quest. "The addition of this patent to our estate further validates our technology."
"The DIOP* ligand family is very effective in producing chiral amines," remarked Professor Xumu Zhang, CTO of Chiral Quest.
Other news from the department business & finance
